相关实验视频

Updated: Jul 13, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

对于转移性割抵抗性前列腺癌的第二次多塞塔塞尔再试验:一个病例报告

Wei Ning¹, Pengkang Chang¹, Ji Zheng¹

¹Department of Urology, Second Affiliated Hospital, Army Medical University, Chongqing, China.

Frontiers in oncology

|October 13, 2023

概括

第二次多塞塔克塞尔重试 (DR) 对转移性割抵抗性前列腺癌 (mCRPC) 患者有希望,提供生存益处和良好的泌尿功能. 这种方法为昂贵的基因检测和活检提供了有价值的替代方案.

科学领域:

在瘤学瘤学.
泌尿器科泌尿器科泌尿器科泌尿器科

背景情况:

转移性割抵抗性前列腺癌 (mCRPC) 治疗已经发展出新的激素药物和PARP抑制剂.
在对多塞塔克塞尔敏感的前列腺癌中,多塞塔克塞尔重试 (DR) 具有重要意义.
关于第二次DR在mCRPC中的有效性和安全性的数据有限.

研究的目的:

报告第二次多塞塔克塞尔在mCRPC患者的疗效和安全性.
评估第二次DR对无进展生存率,总生存率和下尿路功能的影响.

主要方法:

一个单个mCRPC患者的病例报告.
在之前的基于多塞塔克塞尔的疗法后,第二次多塞塔克塞尔的再给药.

主要成果:

患者经历了无进展生存和整体生存的好处.
患者保持了良好的下游泌尿道功能.
治疗与可接受的安全性有关.

结论:

第二次dcetaxel重试是一种可行的mCRPC后期治疗选择.
它为昂贵的多基因检测和活检提供了替代方案.
对选择的mCRPC患者来说,考虑第二次DR可能是有益的.

关键词:

案例报告案例报告后一线治疗后一线治疗转移性割抵抗性前列腺癌 (mCRPC) 是一种前列腺癌 (PCa) 是一种癌症.第二次多塞塔克塞尔再挑战 (DR)

更多相关视频

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...